Reports reveal a significant surge in medicine prices in Iran across various pharmaceutical categories. The sharp price hikes affected 82 pharmaceutical products from a major domestic manufacturer. Specifically, the price of Donepezil tablets increased by nearly 543 percent. Meanwhile, Clarithromycin recorded a steep 308 percent rise during the same period.
These dramatic price increases have sparked widespread public concern over rising healthcare costs. The average price increase across all affected products reached approximately 120 percent. Therefore, patients and industry observers have expressed deep concerns about medical affordability nationwide. However, the Food and Drug Administration swiftly addressed these growing financial concerns.
Mohammad Hashemi, a spokesperson for the agency, strongly denied reports of a new wave of price increases. Furthermore, he clarified that recent foreign exchange policy changes apply only to certain intermediate materials. Therefore, authorities rejected claims that the government had completely eliminated preferential exchange rates for pharmaceuticals. Consequently, officials insisted that key healthcare subsidies remain largely intact for essential drug production.
The Health Ministry reaffirmed its commitment to protecting vulnerable patients from rising costs. Specifically, the government allocated foreign currency for raw materials at previous annual levels. Furthermore, the administration continues to subsidize crucial life-saving medications to maintain healthcare system stability. Therefore, officials urged the public not to panic over ongoing pharmaceutical supply concerns.
Debate over foreign exchange allocations for domestic pharmaceuticals has continued for months. Earlier this year, regulators removed preferential exchange rates for certain over-the-counter and non-chronic medications. Additionally, authorities phased out subsidies for select low-cost formulations and licensed international pharmaceuticals. Consequently, these policy changes triggered noticeable price adjustments at local pharmacies in recent months.
Removing preferential exchange rates gradually increases operating costs for domestic pharmaceutical manufacturers. However, government planners argue that targeted subsidy reductions help optimize limited foreign currency reserves. Furthermore, officials promised that essential prescription medications would retain priority funding through official channels. Therefore, regulatory bodies continue monitoring local distribution networks to prevent illegal price increases.
Balancing fiscal constraints with public healthcare needs remains a complex policy challenge. Analysts anticipate further regulatory adjustments as health authorities manage evolving currency constraints. Moving forward, parliament and health officials plan additional reviews to refine domestic healthcare subsidies. Meanwhile, pharmaceutical manufacturers are navigating shifting regulatory frameworks while attempting to maintain stable drug production.